We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Phoenix Group Holdings Plc | LSE:PHNX | London | Ordinary Share | GB00BGXQNP29 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
4.60 | 0.85% | 546.80 | 546.60 | 547.00 | 550.20 | 541.20 | 544.20 | 1,198,279 | 12:11:45 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Life Insurance | -34.59B | -1.83B | -1.8270 | -2.99 | 5.47B |
Date | Subject | Author | Discuss |
---|---|---|---|
28/12/2016 18:24 | Significant purchase by director associate. | rcturner2 | |
22/12/2016 13:46 | RCT2,I believe you are correct on the Dividend.The actual quote from memory was 50.15p. | garycook | |
22/12/2016 13:30 | One thing that might be holding the share back is that the current level of the dividend is on one level an unknown quantity. Although I assume that it will be about 50p, until Phoenix actually declare their next dividend no one knows for sure. | rcturner2 | |
22/12/2016 09:31 | Encomium - strewth Jonwig, would hate to play you at Scrabble! Will try to get that one into general conversation over Christmas....will help to cement it into a diminishing brain... | skyship | |
21/12/2016 12:45 | Not to be confused with Echium! | skinny | |
21/12/2016 12:44 | Sounds like an enema doesn't it. Painless but not discussed in polite company. | jonwig | |
21/12/2016 12:42 | I had to look it up. | rcturner2 | |
21/12/2016 12:10 | "He received an encomium". Sounds awfully painful. Did it require a general anaesthetic? ;-) | speedsgh | |
21/12/2016 10:30 | He received an encomium, so probably not. | jonwig | |
21/12/2016 09:38 | Is the recent director departure in any way significant?, it seemed quite sudden. | essentialinvestor | |
21/12/2016 07:09 | I doubled up on this yesterday. | rcturner2 | |
20/12/2016 13:14 | If Blackrock has topped up.Then they know its good value. | garycook | |
16/12/2016 16:20 | Thanks, hiddendepths, I knew we were below the pre-rights price was wasn't sure how much. I even managed to pick up an odd amount to get me back to a round number (458 shares) at under £7 which was well over a 7% yield based on the estimated 50p divi. | stun12 | |
16/12/2016 13:50 | hiddendepths, on the button. | edmundshaw | |
16/12/2016 10:10 | hiddendepths.I believe you are totally correct. | garycook | |
16/12/2016 10:03 | Just looking at this stock. FWIW The share price has been weak because of the dilution effect of the rights issue, sometimes known as the bonus element of the rights. This is how to get the theoretical ex rights price. Before the rights was announced, holders had 12 shares (or a multiple thereof!)valued at 880p/share = £105.60 They receive 7 more shares at the 508p each = £35.56 So the new holding is 19 shares worth 105.60 + 35.56 =141.16 This is equivalent to 743p per share, known as the theoretical ex rights price and is the equivalent of the old 880p price. So the shares are down about 3%, probably due to some insitutions reducing their weightings back to where they were before taking the extra shares. This is a normal and temporary overhang and should be corrected in due course. | hiddendepths | |
13/12/2016 16:00 | up 6p on fire Phoenix Grp Hldgs Regulatory Consent - Abbey Life Acquisition RNS Number : 7468R Phoenix Group Holdings 13 December 2016 REGULATORY APPROVAL - ABBEY LIFE ACQUISITION Phoenix Group Holdings 13 December 2016 Phoenix Group Holdings announces that the Prudential Regulation Authority has consented to the acquisition of Abbey Life Assurance Company Limited | orinocor | |
08/12/2016 09:46 | This share has been left behind in the recent rerating of financial stocks. Any reasons? | rl34870 | |
06/12/2016 10:11 | A brief mention of Phoenix in the IC, in an article about rights issues: "Phoenix Group's recent decision to buy Abbey Life for £935m looks to be a much shrewder move. After much media speculation, the life insurance fund specialist finally convinced Deutsche Bank to cede its ownership for 23 per cent below the traditional measure of the book's value. Deutsche's perilous financial situation made it an eager seller, leaving Phoenix, and those who backed the £735m rights issue, with a potential bargain. Abbey Life's unit-linked vehicles require less capital than guaranteed products such as annuities, so there's a chance it will lift Phoenix's Solvency II ratio. Marcus Barnard at Numis reckons the acquisition could boost future cash flows by £1.6bn, and ensure that the extremely attractive dividend continues to grow. Based on these estimates, the shares, which have barely moved since the agreement was first announced, are worth picking up." | rcturner2 | |
01/12/2016 11:26 | Weakness here may just be general market jitters due to the Italian referendum this week-end. | orinocor | |
01/12/2016 09:07 | Brief written interview (2 pages) with Phoenix Life's Andy Moss... Firing Line: Phoenix Life's Andy Moss - | speedsgh | |
01/12/2016 07:32 | Anything under 750p is a bargain in my opinion. | rcturner2 | |
01/12/2016 06:51 | Regarding the share price, MCEV is sensitive to interest rate increases/swap rates. There's reference to this in the annual reports and we discussed it here, though not recently. The market tends to get jitters from time to time about this sort of thing. PHNX has made two decent acquisitions this year. Chesnara has just bought L&G's Dutch life business at a very big discount. I think Solvency II is causing big companies to dispose of non-core operations at a discount, benefiting both parties. The only constraints will be the appetite of shareholders for more fundraising and the time and effort in integrating new operations. I imagine there won't be more for a while. | jonwig |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions